Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia

Journal of Chemotherapy
A T Eltahawy

Abstract

The resistance pattern of 105 consecutive strains of Streptococcus pneumoniae isolated from patients at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia over a 2-year period (March 1998 to February 2000) was determined with the minimal inhibitory concentration (MIC) method using E-test. Overall 6.7% of the isolates were penicillin resistant (MICs > or = 2 mg/L), and 51% were intermediate (MICs 0.12-1 mg/L). The resistance rates to ampicillin, cefotaxime, ceftriaxone, imipenem, erythromycin and clarithromycin were 8.6%, 8.6%, 4.7%, 3.8%, 13%, and 21% respectively. High-level resistance was noted against cotrimoxazole and chloramphenicol, 76% and 68% respectively. Only 2.8% of S. pneumoniae were resistant to amoxycillin-clavulanate; no resistance to vancomycin was observed. Against penicillin-intermediate pneumococcal strains, vancomycin, ceftriaxone, cefotaxime and amoxycillin-clavulanate were the most active compounds. Against penicillin-resistant pneumococci, vancomycin was the most powerful agent, amoxycillin-clavulanate was half as active, whereas ceftriaxone, cefotaxime and imipenem were 4-fold less active than vancomycin. Fifty-six (53%) of the 105 pneumococcal strains were multi-drug resistant.

References

Sep 1, 1992·The Journal of Antimicrobial Chemotherapy·J LiñaresR Martín
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J LiñaresR Martin
Dec 1, 1991·The Journal of Antimicrobial Chemotherapy·F BaqueroE Loza
Aug 1, 1990·The American Review of Respiratory Disease·J PachonA Verano
Apr 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H J LeeK W Choi
Nov 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M NavaS Uriz
Apr 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T J Marrie
Feb 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C C John
Jun 15, 1994·JAMA : the Journal of the American Medical Association·R F BreimanR R Facklam
Jul 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·F Baquero
Mar 3, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I ParaskakisD A Kafetzis
May 2, 2000·Journal of Chemotherapy·A M ShiblA O Osoba
Feb 28, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anna MarcheseGian Carlo Schito
Sep 1, 1995·International Journal of Antimicrobial Agents·M N ChowdhuryA M Kambal

❮ Previous
Next ❯

Citations

Sep 15, 2015·Journal of Epidemiology and Global Health·Yagob AlmazrouWilliam P Hausdorff
Jul 5, 2012·Journal of Chemotherapy·Saber YezliZiad A Memish
May 1, 2002·Current Opinion in Pulmonary Medicine·Rumina Hasan, Sardar Ijlal Babar
Jun 28, 2005·Annals of Saudi Medicine·Husn H Frayha, Yagob Y Al Mazrou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.